Today: 14 May 2026
PVH stock slips as Supreme Court tariff decision hangs over retailers — what traders watch next
9 January 2026
1 min read

PVH stock slips as Supreme Court tariff decision hangs over retailers — what traders watch next

New York, Jan 9, 2026, 14:33 EST — Regular session

  • PVH shares fell about 4% in afternoon trade, bucking a higher consumer-discretionary sector
  • U.S. Supreme Court said it would not issue a tariffs ruling on Friday; next opinions are due Jan. 14
  • PVH has flagged tariffs as a profit headwind, adding focus to any change in trade policy

PVH Corp shares fell 4.4% to $65.32 on Friday afternoon, extending a choppy week for the Calvin Klein and Tommy Hilfiger owner.

The drop comes as investors wait on U.S. tariff policy, after the Supreme Court said it would not rule on the legality of President Donald Trump’s sweeping tariffs on Friday and is expected to issue its next decisions on Jan. 14.

That matters for import-heavy brands because tariff outcomes can swing costs quickly, while the broader market was leaning risk-on after a softer December U.S. jobs report kept rate-cut expectations in play. “This is a report that’s somewhat within the range of expectations of investors, so they’re not reacting,” Mark Hackett, chief market strategist at Nationwide, told Reuters. Reuters

PVH has already put numbers around the issue. The company said in its most recent quarterly update that its 2025 outlook included an unmitigated tariffs hit of about $65 million to EBIT, or roughly $1.05 per share, partly offset by mitigation actions.

A separate SEC filing on Thursday showed interim CFO Melissa A. Stone reported holding 15,410 PVH shares directly, including restricted stock units, plus stock held through a 401(k) plan.

PVH’s slide stood out against a firmer tape: the consumer discretionary sector ETF XLY was up about 1.1%, while the retail ETF XRT was little changed.

There are risks to both sides of the trade-policy bet. Even investors leaning toward tariff relief have cautioned that a court ruling may not translate into immediate changes on the ground, depending on what the administration does next.

Near term, traders will watch for any tariff-related read-through across apparel and retail, while earnings calendars expect PVH’s next results around late March. The sharper catalyst is Jan. 14, when the Supreme Court is due to return with more opinions.

Stock Market Today

  • Nurix Therapeutics Stock: Is Its Premium 23.3x Price-to-Sales Multiple Justified?
    May 14, 2026, 9:02 AM EDT. Nurix Therapeutics (NRIX) shares rose 1.38% to $16.18 amid mixed recent performance, down 10% year to date but up nearly 69% over one year. The stock trades at a high price-to-sales (P/S) multiple of 23.3x, well above the US biotech average of 9.7x. This premium reflects strong analyst revenue growth forecasts of 42.2% annually, outpacing the broader market. However, Nurix remains loss-making with $295 million in ongoing losses and a $1.65 billion market cap, making it vulnerable to clinical setbacks. Investors should weigh the high growth potential against risks in this early-stage biotech before assuming the premium valuation is sustainable.

Latest articles

Apple Backs Google in EU AI Fight as iPhone Rules Loom

Apple Backs Google in EU AI Fight as iPhone Rules Loom

14 May 2026
Apple warned the European Commission that proposed EU rules forcing Google’s Android to open core features to rival AI assistants could endanger privacy, security, and device performance. The Commission’s feedback period closed Wednesday, with a final decision expected by July 27. Apple argued the measures could set a precedent for its own platforms. Google also opposes the plan, calling it an “unwarranted intervention.”
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

14 May 2026
Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

14 May 2026
POET Technologies signed a supply and joint-development agreement with Lumilens, including a $50 million initial order for optical engines used in AI data-center networks. The companies said cumulative purchases could exceed $500 million over five years. POET shares rose 16% after the news. First engineering samples are expected in late 2026, with production targeted for 2027.
Seagate (STX) stock rebounds toward $300 after Goldman target hike, earnings in focus
Previous Story

Seagate (STX) stock rebounds toward $300 after Goldman target hike, earnings in focus

BitMine (BMNR) stock falls as new CFO/COO joins ahead of shareholder dilution vote
Next Story

BitMine (BMNR) stock falls as new CFO/COO joins ahead of shareholder dilution vote

Go toTop